Acute myocardial infarction
Conditions
Interventions
Patients received standard medication containing 2 mg/day of pitavastaitin as a control group.
Patients received additional 1,800 mg/day of eicosapentaenoic acid as a EPA group.
Sponsors
Kagawa Prefectural Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Acute myocardial infarction patients treated with percutaneous coronary intervention within 24 hours of symptom onset were eligible to study population. Myocardial infarction was diagnosed according to the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.
Exclusion criteria
Exclusion criteria: Exclusion criteria were cardiogenic shock, severe renal insufficiency requiring dialysis or continuous hemofiltration, cardiopulmonary arrest, emergent coronary artery bypass and failure of percutaneous coronary intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point was composite clinical outcomes, including ventricular arrhythmias, paroxysmal atrial fibrillation, re-infarction, stroke and death. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end-point was peak CRP value after PCI, MI size estimated by peak creatine kinase (CK), and left ventricular ejection fraction at 2 weeks after onset of acute MI. | — |
Countries
Japan
Contacts
Public ContactMasayuki Doi
Kagawa Prefectural Central Hospital Cardiology
Outcome results
None listed